Skip to main content

Recent News

Inflammatory bowel disease in spondyloarthritis - does it matter?

Do the clinical features of axSpA patients with and without IBD differ? In Abstract OP0085 at #EULAR2024, De Hooge M et al presented data from the METEOR cohort that identify clinical differences between these two groups. This will be important in order to stratify the management approach in axSpA patients with or without IBD as the emerging therapies have different effects on EMMs.

Read Article
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 ! Amazing pictures to explain cellular level pathophysiology! Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta @bella_mehta (  View Tweet)
#EULAR2024 POS0529 Post-hoc analysis from Phase 2 NOBILITY showed consistent renal response was achieved in Obinutuzumab + SOC vs PBO + SOC across Complete Renal Response definitions and baseline Proteinuria levels. Assuring and looking forward to results next year @RheumNow https://t.co/wKCOP5BgoQ
Md Yuzaiful Md Yusof @Yuz6Yusof (  View Tweet)
#SARD #ILD Who to screen for #rheumatic #diseases For ILD #ACR guidelines Screening May also depend on ILD prevalence Not sure if frequency of screening and how to screen @jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Janet Pope @Janetbirdope (  View Tweet)
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN
PA Juge @Juge_P_A (  View Tweet)
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
Dr. John Cush @RheumNow (  View Tweet)
New hypothesis are explored in #Sjogren #EULAR2024 CB https://t.co/0glF5BGVO5
Annals of the Rheumatic Diseases @ARD_BMJ (  View Tweet)
Major pathogenic characteristics of #Sjogren disease #EULAR2024 CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases @ARD_BMJ (  View Tweet)
Did the patient fail on therapy or are the therapies failing the patient? 🤔 Difficult to to manage psoriatic arthritis: A suggested approach #EULAR2024 NZ https://t.co/lYvXEX7dp3
Annals of the Rheumatic Diseases @ARD_BMJ (  View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Peter Nash @drpnash (  View Tweet)

#Editor’s #Choice @MatsJunek Who #relapses in #ANCA #vasculitis In #Pexivas trial #Renal #failure may be protective from relapses. Seems to be the case in renal #lupus #GN too~my opinion ?Why 🤷 #EULAR2024 #EULARBEST @ARD_BMJ @RheumNow @eular_org @ACR_Journals https://t.co/kUD1qjnwqE
Janet Pope @Janetbirdope (  View Tweet)
I was allocated to bring down the warning, & I did apologise up front to both the EMA and Janet #EULAR2024. It's a tough gig regulating impactful medicines with risk-benefit, especially when our world is full of other medicines with risk-benefit trade-offs (like prednisolone). 2/ https://t.co/6YPhYHbhg8
David Liew @drdavidliew (  View Tweet)
So how do we get from slightly increased numbers of uncommon events in a single study (ORAL Surveillance)? Regulators think differently to us, which partly is the difficulty of a restrictive warning. So being the Aussie I am, I asked - does it pass the 'pub test'? 4/ #EULAR2024 https://t.co/Ih9H87wH22
David Liew @drdavidliew (  View Tweet)
Having said that, the EMA warning has elements making it extremely tough: - still very broad criteria that capture 80% of people who were starting JAKi - the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM
David Liew @drdavidliew (  View Tweet)
My friend the late, great @philipcrobinson and I wrote @TheLancetRheum about what we could learn from COVID about preventative medicine. https://t.co/55j8rduvyn It's worth us thinking how we can do better by our patients. 18/ #EULAR2024 https://t.co/zlDKYngsu0
David Liew @drdavidliew (  View Tweet)
Here's my 'pub test' for whether the warning is appropriate. And, debate aside, I do believe that it behoves any regulator to consider the unintended consequences of their regulation, because regulation has real consequences. 5/ #EULAR2024 https://t.co/aurbAwgl9P
David Liew @drdavidliew (  View Tweet)
The original direct comparison study! https://t.co/hqrPKfNW1y
Bella Mehta @bella_mehta (  View Tweet)
Computer vision/ image analysis is performing very well in rheumatology and can extend help to low resource settings easily! #EULAR2024 https://t.co/8doM7foriM
Bella Mehta @bella_mehta (  View Tweet)